Better compliance to antihypertensive medications reduces cardiovascular risk

Journal of Hypertension

Volumn 29, Issue 3, 2011, Pages 610-618

  Corrao, Giovanni ^a   Parodi, Andrea ^a   Nicotra, Federica ^a   Zambon, Antonella ^a   Merlino, Luca ^b   Cesana, Giancarlo ^a   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Operative Unit of Territorial Health Services   (Italy)

Author keywords

adherence; antihypertensive agents; cardiovascular disease; discontinuation; persistence; primary prevention

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ORGANIC NITRATE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 79951677672     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328342ca97     Document Type: Article

References (56)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., for The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187.
2. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17. (Pubitemid 38031904)
3. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11-19. (Pubitemid 38293521)
4. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1498. (Pubitemid 46918838)
5. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21:1635-1640. (Pubitemid 37076345)
6. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360. (Pubitemid 35341298)
7. Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al., CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338-1344. (Pubitemid 38691759)
8. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18:1691-1699.
9. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160:41-46. (Pubitemid 29054225)
10. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16:439-444. (Pubitemid 34685595)
11. Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19:607-613. (Pubitemid 41131661)
12. Fitz-Simon N, Bennett K, Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Therapeut Clin Risk Manag 2005; 1:93-106.
13. Mazzaglia G, Mantovani L, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23:2093-2100. (Pubitemid 41830406)
14. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107. (Pubitemid 41830407)
15. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of hypertensive drugs among newly diagnosed hypertensive patients in UKgeneral practice. J Hypertens 2006; 24:1193-1200. (Pubitemid 43772328)
16. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20:72-80. (Pubitemid 46219403)
17. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824. (Pubitemid 351354932)
18. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117. (Pubitemid 351731741)
19. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12:239-245. (Pubitemid 47400613)
20. Krousel-Wood M, Thomas S,Muntner P, Morisky D.Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19:357-362. (Pubitemid 38916494)
21. Breekveldt-Postma NS, Penning-Van Beest FJ, Siiskonen SJ, Koerselman J, Klungel OH, Falvey H, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin 2008; 24:1025-1031. (Pubitemid 351579159)
22. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40:794-811.
23. HoPM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Int Med 2006; 166:1836-1841. (Pubitemid 44455165)
24. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113:203-212
25. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297:177-186. (Pubitemid 46089734)
26. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155:772-779. (Pubitemid 351410514)
27. Breekveldt-Postma NS, Penning-Van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24:121-127. (Pubitemid 351160245)
28. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185:487-489. (Pubitemid 44756209)
29. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-530. (Pubitemid 40847288)
30. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
31. Kettani FZ, Dragomir A, CôtéR, Roy L, Bérard A, Blais L, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40:213-220.
32. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266:207-218.
33. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69:74-84.
34. Dragomir A, Cô téR, Roy L, Blais L, Lalonde L, Bérard A, Perreault S. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48:418-425.
35. Corrao G, Cesana G, Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008; 2:117-125.
36. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medical adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15:565-574. (Pubitemid 44336271)
37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-619.
38. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A, for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
39. Asplund K, Bonita R, Kuulasmaa K, Rajakangas AM, Schaedlich H, Suzuki K, et al. Multinational comparisons of stroke epidemiology: evaluation of case ascertainment in the WHO MONICA stroke study. Stroke 1995; 26:355-360.
40. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons; 1995.
41. Greenland S. Sensitivity analysis, Monte-Carlo risk analysis and Bayesian uncertainty assessment. Risk Anal 2001; 21:579-583. (Pubitemid 34101530)
42. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, Newman MF. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Pychosom Med 2004; 66:305-315. (Pubitemid 38668397)
43. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101-2107. (Pubitemid 30482715)
44. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. Arch Intern Med 2000; 160:1261-1268. (Pubitemid 30252771)
45. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications. The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002; 17:504-511. (Pubitemid 34989157)
46. Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008; 66:706-716.
47. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535. (Pubitemid 37410190)
48. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospecive epidemiological studies. BMJ 2009; 338:b1665.
49. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed New York: John Wiley & Sons; 2000. pp. 219-222.
50. Corrao G, Zambon A, Nicotra F, Fornari C, La Vecchia C, Mezzanzanica M, et al. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Maturitas 2007; 57:315-324. (Pubitemid 46891706)
51. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47:1039-1048. (Pubitemid 44289157)
52. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105:488-495. (Pubitemid 8112070)
53. Poluzzi E, Strahinja P, Vargiu A, Chiabrando G, Silvani MC, Motola D, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61:603-609. (Pubitemid 41414244)
54. Morenoff JD, House JS, Hansen BB, Williams DR, Kaplan GA, Hunte HE. Understanding social disparities in hypertension prevalence, awareness, treatment, and control: the role of neighborhood context. Soc Sci Med 2007; 65:1853-1866. (Pubitemid 47516620)
55. Petrelli A, Gnavi R, Marinacci C, Costa G. Socioeconomic inequalities in coronary heart disease in Italy: a multilevel population-based study. Soc Sci Med 2006; 63:446-456. (Pubitemid 43841748)
56. Corrao G, Zambon A, Parodi A, Mezzanzanica M, Merlino L, Cesana G, Mancia G. Do socioeconomic disparities affect accessing and keeping antihypertensive drug therapy? Evidence from an Italian population-based study. J Hum Hypertens 2009; 23:238-244.